Clinical Trials Logo

Hemorrhagic Shock clinical trials

View clinical trials related to Hemorrhagic Shock.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT02821364 Withdrawn - Peritonitis Clinical Trials

Philadelphia Immediate Transport in Penetrating Trauma Trial

PIPT
Start date: February 1, 2020
Phase: N/A
Study type: Interventional

PIPT Trial (Philadelphia Immediate Transport in Penetrating Trauma Trial) A prospective randomized clinical trial comparing pre-hospital procedures to immediate transportation in patients with penetrating injury and shock.

NCT ID: NCT01973504 Withdrawn - Trauma Clinical Trials

Phase 2c Dose Comparison Study of MP4OX in Trauma

Start date: December 2013
Phase: Phase 2
Study type: Interventional

MP4OX is being developed as an ischemic rescue therapy to perfuse and oxygenate tissues at risk during hemorrhagic shock. MP4OX is a pegylated hemoglobin-based colloid designed to improve perfusion and target delivery of oxygen to ischemic tissues. This study will evaluate safety and efficacy of MP4OX treatment, in addition to standard therapy, in trauma patients suffering from lactic acidosis due to severe hemorrhagic shock.

NCT ID: NCT01221389 Withdrawn - Trauma Clinical Trials

Study Using Plasma for Patients Requiring Emergency Surgery

SUPPRES
Start date: March 2012
Phase: Phase 4
Study type: Interventional

Information on the management of casualties from the ongoing conflicts in Afghanistan and Iraq has brought in to question the traditional approach to blood transfusion in hemorrhaging patients. Present recommendations for when to transfuse plasma products is when coagulation tests become abnormal. The proposed trial will investigate whether the more aggressive plasma transfusion strategies as advocated from researchers based on the Central Asian conflicts is valid. Since a study to determine the full impact of an altered plasma transfusion practice would require thousands of patients, a feasibility trial is appropriate and is being proposed. The hypotheses are thus: Primary Hypothesis- A multicentre trial that investigates the earlier use of plasma in patients with hemorrhagic shock going for emergency surgery will be feasible. Secondary Hypotheses- The early use of a universal donor blood plasma (AB+ plasma) in patients with shock due to blood loss (i.e. hemorrhagic) going for emergency surgery will reduce overall exposure to the total number of blood donor products (so-called allogeneic blood exposure). A reduction in allogeneic blood exposure would then reduce the total number of blood transfusion-related complications. The early use of this plasma product is safe and will not increase the incidence of blood clotting or other transfusion-related complications.